Conference Reports for NATAP

Back

Conference on Retroviruses and Opportunistic Infections San Francisco, CA March 9-12 2025     HIV Treatment, Long-Acting, New Drug Development   Update on Merck's Late-Stage HIV Pipeline - (03/11/25)   Update on Update on the Long-Acting HIV Treatment and Prevention Pipeline - (03/11/25)   MK-8527 PK/PD Threshold and Phase 2 Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis - (03/11/25)   Current status of LA/ER Cabotegravir (CAB) and Rilpivirine including pipeline report - (03/11/25)   In Vitro Resistance Profile for GS-1720, a Potent Once-Weekly Oral INSTI in Clinical Development - (03/11/25)   Modeling Accurately Predicts Efficacious Islatravir QW Dose with no Lymphocyte and CD4 Changes - (03/11/25)   Pharmacokinetic Modeling of Missed Dose Scenario of Oral Weekly Islatravir Plus Lenacapavir - (03/11/25)   Bictegravir + Lenacapavir: Baseline and Week 48 Resistance Analyses in ARTISTRY-1 Phase 2 - (03/11/25)   Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks - (03/11/25)   Clinical Outcomes Among Virologically Suppressed Women Receiving CAB+RPV LA in the OPERA Cohort - (03/11/25)   Long-term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort - (03/11/25)   Outcomes on Cabotegravir + Rilpivirine in Suppressed People with HIV (PWH) in TRIO Health US Cohort - (03/11/25)   Aging, Comorbidities   Risk of Incident Hypertension with Common Antiretroviral Agent Combinations in the OPERA Cohort - (03/11/25)   Renal Outcomes in People With HIV-1 and Renal Impairment Treated With B/F/TAF in Randomized Trials - (03/11/25)   No Increased Risk for Hypertension with CAB-LA Compared to TDF/FTC for PrEP: Results from HPTN 084 - (03/11/25)   DoxyPEP   Young Black Sexually Minoritized Men Living with HIV, Substance Use, and Syphilis Want Doxy-PEP - (03/11/25)   Characteristics of Breakthrough Chlamydia Cases among Cisgender Women Assigned to Doxycycline Postexposure Prophylaxis - (03/11/25)   Post-Exposure Prophylaxis With Doxycycline (DoxyPEP) in a Cohort of High-Risk MSM: The PRIDOX Study - (03/11/25)   Antimicrobial Resistance of N. gonorrhoeae at a Community-Based Sexual Health Clinic, 2023-2024 - (03/11/25)   Hepatitis, Liver   Safety and Efficacy of Glecaprevir/Pibrentasvir for 8 Weeks for Treatment of Acute Hepatitis C Virus Infection in People Living with HIV - (03/11/25)   Impact of HIV Infection on the Dynamics of Liver Stiffness After HCV Cure - (03/11/25)   "HIV Cure", Viral Control   The Barrier to HIV-1 Escape from Broadly Neutralizing Antibodies Varies Between Different HIV-1 Isolates - (03/11/25)